RHOA
RHOA (Transforming protein RhoA) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Gastric & gastro-oesophageal junction cancer, Bladder & urothelial cancer and 5 more.
Overview
Small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state. Mainly associated with cytoskeleton organisation, in active state binds to a variety of effector proteins to regulate cellular responses such as cytoskeletal dynamics, cell migration and cell cycle. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibres.
CIViC holds 3 clinical evidence items and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.34, genetic association 0.03, somatic mutation 0.95). IntOGen calls it a driver in 14 cohorts (13 activating, 1 loss-of-function), covering Burkitt Lymphoma, Bladder Urothelial Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Head and Neck Squamous Cell Carcinoma, Malignant Lymphoma, Non-Hodgkin Lymphoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · RHOA (Transforming protein RhoA) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Gastric & gastro-oesophageal junction cancer, Bladder & urothelial cancer and 5 more.
- 1 · What it is
RHOA (Transforming protein RhoA) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Gastric & gastro-oesophageal junction cancer, Bladder & urothelial cancer and 5 more.
- 2 · What goes wrong in cancer
Small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state.
- 3 · How drugs use it
No product in this corpus aims at RHOA yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:667 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P61586 (protein name, function text, keywords and locations (REST API)); CIViC gene RHOA (3 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Stomach Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000067560 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: gastric cancer 0.65, urinary bladder cancer 0.56, non-Hodgkin lymphoma 0.72, Burkitt lymphoma 0.53, leukaemia 0.56 (GraphQL API, CC0)); IntOGen RHOA (driver in 14 cohorts (Act 13, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state. Mainly associated with cytoskeleton organisation, in active state binds to a variety of effector proteins to regulate cellular responses such as cytoskeletal dynamics, cell migration and cell cycle. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibres. Involved in a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Plays an essential role in cleavage furrow formation. Required for the apical junction formation of keratinocyte cell-cell adhesion. Location: Cell membrane; Cytoplasm, cytoskeleton; Cleavage furrow; Cytoplasm, cell cortex (UniProt). Locus 3p21.31 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.72 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.65 with gastric cancer (MONDO_0001056); CIViC evidence names this disease
- Bladder & urothelial cancer: Open Targets association 0.56 with urinary bladder cancer (MONDO_0001187); IntOGen driver in 2 cohorts (BLCA)
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Mesothelioma: IntOGen driver in 1 cohort (PLMESO)
- Prostate cancer: IntOGen driver in 1 cohort (PRAD)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 13 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 3 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"RHOA" OR ABSTRACT:"RHOA" OR TITLE:"ras homolog family member A" OR ABSTRACT:"ras homolog family member A" OR TITLE:"Transforming protein RhoA" OR ABSTRACT:"Transforming protein RhoA" OR TITLE:"Rho12" OR ABSTRACT:"Rho12" OR TITLE:"RHOH12" OR ABSTRACT:"RHOH12" OR TITLE:"ARH12" OR ABSTRACT:"ARH12") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RHOA, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetNBN
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), CIViC, Gastric & gastro-oesophageal junction cancer.
- TargetNSD2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Bladder & urothelial cancer, CIViC.
- TargetDDX3X
Shares Mesothelioma, Leukaemia (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetCREBBP
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Bladder & urothelial cancer, CIViC.
- TargetGNA13
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), Bladder & urothelial cancer, CIViC.
- TargetID3
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, IntOGen.
- TargetCCND3
Shares Burkitt lymphoma, Leukaemia (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetPRKCB
Shares Leukaemia (all types), CIViC, IntOGen, Gastric & gastro-oesophageal junction cancer.